23,505 Shares of Cytokinetics, Incorporated $CYTK Bought by Sanders Morris Harris LLC

Key Points

• Sanders Morris Harris LLC bought a new 23,505-share stake in Cytokinetics during the third quarter, valued at approximately $1.55 million. Other institutional investors also increased or initiated positions.
• New Phase 3 ACACIA-HCM data showed aficamten improved exercise capacity across multiple patient groups with non-obstructive hypertrophic cardiomyopathy, supporting its potential regulatory and commercial outlook.
• Cytokinetics shares recently traded at $63.43, while analysts maintained a largely bullish view: 18 of 20 analysts rated the stock a Buy, with a consensus “Moderate Buy” rating and a target price near $105.

Sanders Morris Harris LLC bought a new stake in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 23,505 shares of the biopharmaceutical company's stock, valued at approximately $1,549,000.

Several other large investors also recently made changes to their positions in CYTK. Principal Financial Group Inc. increased its position in Cytokinetics by 11.9% in the 1st quarter. Principal Financial Group Inc. now owns 1,093,485 shares of the biopharmaceutical company's stock valued at $72,072,000 after acquiring an additional 116,593 shares in the last quarter. ADAR1 Capital Management LLC lifted its position in shares of Cytokinetics by 17.1% during the first quarter. ADAR1 Capital Management LLC now owns 632,556 shares of the biopharmaceutical company's stock worth $41,692,000 after purchasing an additional 92,390 shares in the last quarter. Siren L.L.C. acquired a new position in shares of Cytokinetics during the first quarter worth approximately $40,466,000. Handelsbanken Fonder AB lifted its position in shares of Cytokinetics by 63.8% during the second quarter. Handelsbanken Fonder AB now owns 405,000 shares of the biopharmaceutical company's stock worth $34,502,000 after purchasing an additional 157,700 shares in the last quarter. Finally, E. Ohman J or Asset Management AB grew its stake in shares of Cytokinetics by 1.3% during the second quarter. E. Ohman J or Asset Management AB now owns 304,611 shares of the biopharmaceutical company's stock valued at $25,950,000 after purchasing an additional 3,849 shares during the last quarter.

Key Cytokinetics News

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: New analyses from the Phase 3 ACACIA-HCM study showed aficamten improved exercise-capacity measures and benefited multiple patient responder groups with non-obstructive hypertrophic cardiomyopathy. The data also supported the drug’s dose-adjustment strategy and safety profile, strengthening the potential regulatory and commercial case for aficamten. ACACIA-HCM Data
• Positive Sentiment: Analyst and market commentary has focused on aficamten’s multi-domain benefits and the possibility that the heart drug could materially improve Cytokinetics’ long-term outlook. The stock has a consensus “Moderate Buy” rating and an average price target of $106.06, well above the recent trading range, although approval and commercialization risks remain. Aficamten HFSA Data
• Neutral Sentiment: CEO Robert Blum sold 7,500 shares for approximately $471,600 at an average price of $62.88. The transaction was conducted under a pre-arranged Rule 10b5-1 plan, and Blum retained 278,544 shares, limiting its significance as a bearish signal. Nevertheless, the sale may create modest short-term pressure on investor sentiment. SEC Form 4 Filing

Insider Activity

In other news, Director B. Parshall sold 5,000 shares of the firm's stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $71.48, for a total transaction of $357,400.00. Following the sale, the director owned 10,784 shares of the company's stock, valued at $770,840.32. This trade represents a 31.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Fady Malik sold 3,500 shares of the firm's stock in a transaction dated Tuesday, October 6th. The stock was sold at an average price of $61.38, for a total value of $214,830.00. Following the sale, the executive vice president directly owned 153,902 shares in the company, valued at approximately $9,446,504.76. This represents a 2.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 191,426 shares of company stock worth $13,601,885 in the last 90 days. Corporate insiders own 2.60% of the company's stock.

Cytokinetics Stock Up 2.9%

NASDAQ CYTK traded up $1.81 during trading on Wednesday, reaching $63.43. 2,095,733 shares of the stock traded hands, compared to its average volume of 2,140,029. Cytokinetics, Incorporated has a fifty-two week low of $54.30 and a fifty-two week high of $88.31. The firm has a market cap of $7.89 billion, a price-to-earnings ratio of -8.79 and a beta of 0.41. The stock's 50-day moving average price is $71.13 and its 200 day moving average price is $73.27.

Cytokinetics (NASDAQ:CYTK - Get Free Report) last posted its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.50) earnings per share for the quarter, topping the consensus estimate of ($1.63) by $0.13. The firm had revenue of $28.62 million during the quarter, compared to analyst estimates of $17.59 million. The company's revenue for the quarter was down 57.1% on a year-over-year basis. During the same quarter last year, the business posted ($1.12) earnings per share. Analysts anticipate that Cytokinetics, Incorporated will post -5.98 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. JPMorgan Chase & Co. raised their price target on shares of Cytokinetics from $97.00 to $103.00 and gave the company an "overweight" rating in a report on Thursday, August 13th. Morgan Stanley raised Cytokinetics from an "overweight" rating to a "buy" rating in a report on Tuesday, September 1st. Royal Bank Of Canada upped their price objective on Cytokinetics from $112.00 to $113.00 and gave the stock an "outperform" rating in a report on Thursday, October 8th. Wall Street Zen upgraded Cytokinetics from a "sell" rating to a "hold" rating in a research report on Monday. Finally, Citigroup reissued a "market outperform" rating on shares of Cytokinetics in a research note on Friday, August 7th. Eighteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $105.44.

About Cytokinetics

Cytokinetics, Incorporated is a biopharmaceutical company focused on discovering and developing medicines that improve muscle function. The company applies muscle biology and molecular pharmacology to develop therapies for cardiovascular and neuromuscular diseases in which impaired muscle performance contributes to disease progression or disability.

Its lead programs include aficamten, a next-generation cardiac myosin inhibitor being developed for hypertrophic cardiomyopathy, and other investigational compounds designed to modulate the activity of cardiac or skeletal muscle.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.